3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Neurofibromatosis 1
6
Neoplasm Metastasis
6
Solid Tumours
5
Neoplasms
5
Melanoma
5
Neurofibroma, Plexiform
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Solid Tumors
1
Renal Insufficiency
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Muscle Invasive Bladder Cancer
1
Locally Advanced or Metastatic Solid Tumors
1
Kidney Neoplasms
1
Healthy Volunteers Pharmacokinetic Study
1
Disease Progression
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Advanced Non Small Cell Lung Cancer
1
Advanced Cancer
1
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
AZD 6244
×
Clear all
NCT01974752
2017-01-05
SUMIT
AstraZeneca
Phase 3
Completed
152 enrolled
14 charts